Merck wins second Vioxx trial

Share this article:
The jury in the Atlantic City, N.J. Vioxx trial has found Merck not liable.
Merck lawyers persuaded jurors that the heart attack suffered by Idaho postal worker Frederick Humeston was unrelated to his two-month use of Vioxx, citing a host of other cardiovascular risk factors suffered by the plaintiff.
The verdict, following the $253 million decision against Merck in plaintiff-friendly Angleton, Texas last August, should provide a big boost for morale at Merck and could have implications for future Vioxx litigation, as a string of wins for Merck or a mixed record could deter trial lawyers from pursuing lengthy and costly lawsuits against the company. The firm still faces more than 6,000 suits alleging injuries due to Vioxx, which Merck pulled little more than a year ago after studies showed the drug increased cardiovascular risks in patients with preexisting heart conditions.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.